OncoSenX
OncoSenX develops targeted cancer therapies that use a proteo-lipid vehicle to deliver plasmid DNA, inducing apoptosis in cancer cells based on their transcriptional activity. Its approach aims to precisely target solid tumors while minimizing side effects and avoiding harm to healthy cells.
Facts
- HQ
- Seattle, Washington
- Sectors
- Biotechnology, Therapeutics, Oncology
- Stage
- Seed
- Members see funding amounts. .
Is this your organization? Claim it
Executives
-
Eric Garcia Executive, Chief Operating Officer
-
Matthew Scholz Executive, Chief Executive Officer
-
Stephen Hilbert Executive, Chief Business Officer